Design Therapeutics, Inc.
No SEC Form 4 filings for $DSGN in the last 30 days.
See all $DSGN insider activity →Wells Fargo initiated Design Therapeutics with an overweight rating, citing potential best-in-disease functional improvement for its Friedreich ataxia candidate, DT-216P2, based on RESTORE-FA study results. The bank set a $26 price target, implying ~112% upside.
Truist trimmed MAA's price target to $142, citing Sun Belt job growth concerns. TD Cowen upgraded Rivian to Buy with a $20 target, projecting strong R2 demand. RBC raised Design Therapeutics' target to $14 ahead of 2026 data. MAA yields 4.56%, Rivian is down 17.18% YTD, and Design Therapeutics is up 189.19% YTD.
Design Therapeutics, Inc. (DSGN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Design Therapeutics Provides RESTORE-FA Clinical Development Update and Reports Second Quarter 2026 Financial Results RESTORE-FA trial modifications build on positive four-week data; expect to share data based on 12 weeks of dosing in the first quarter of 2027 Patien
Over the past 7 days, AlphAI's AI scored 1 news story mentioning DSGN (Design Therapeutics, Inc.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent DSGN coverage spans financial news, earnings and corporate actions.
Analyst upgrade with a high price target suggests potential upside.
Incremental target raise increases optimism into H2 2026 readouts for two programs.
The filing adds fresh clinical and financial runway details that can shift near-term expectations for readouts and trial progression.
Routine corporate governance vote results; limited direct fundamental change, but confirms board/auditor continuity for the fiscal year.
The scheduled release of trial data could lead to increased volatility in DSGN stock around the event date. Positive results may boost the stock, while negative or inconclusive data could depress it.
AlphAI scores every news story that mentions DSGN with an AI model for sentiment and relevance, and aggregates insider trades from Design Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Wells Fargo initiated Design Therapeutics with an overweight rating, citing potential best-in-disease functional improvement for its Friedreich ataxia candidate, DT-216P2, based on RESTORE-FA study results. The bank set a $26 price target, implying ~112% upside.
1 min readTruist trimmed MAA's price target to $142, citing Sun Belt job growth concerns. TD Cowen upgraded Rivian to Buy with a $20 target, projecting strong R2 demand. RBC raised Design Therapeutics' target to $14 ahead of 2026 data. MAA yields 4.56%, Rivian is down 17.18% YTD, and Design Therapeutics is up 189.19% YTD.
6 min readDesign Therapeutics, Inc. (DSGN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Design Therapeutics Provides RESTORE-FA Clinical Development Update and Reports Second Quarter 2026 Financial Results RESTORE-FA trial modifications build on positive four-week data; expect to share data based on 12 weeks of dosing in the first quarter of 2027 Patien
4 min readDesign Therapeutics, Inc. (DSGN) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. 8-K 0001807120 false 0001807120 2026-06-09 2026-06-09 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 09,
2 min readDesign Therapeutics (Nasdaq: DSGN) plans to host an investor webcast on Monday, May 18, 2026, at 8:00 a.m. ET to announce data from its ongoing Phase 1/2 RESTORE-FA trial. This trial is evaluating DT-216P2 for the treatment of Friedreich’s ataxia. The webcast will be accessible through the company's website.
3 min readDesign Therapeutics reported its Q1 2026 financial results, closing the quarter with $222.8 million in cash, which is expected to fund operations into 2029. The company highlighted ongoing clinical trials, including the RESTORE-FA multiple-ascending-dose trial for DT-216P2 and a Phase 2 DT-168 biomarker study, with key data readouts anticipated in H2 2026. Additionally, dosing for DT-818 (DM1) is expected to begin in H1 2026, and David Shapiro, M.D., was appointed to the board to enhance clinical and regulatory expertise.
4 min readDesign Therapeutics (NASDAQ:DSGN) recently hit a new 52-week high of $12.98, trading at $12.9240 with a market capitalization of approximately $776.4 million. The company reported a Q4 EPS of ($0.27), exceeding estimates, and analysts have a "Moderate Buy" consensus with an average price target of $15.20. Institutional investors hold a significant 56.64% stake in the company.
3 min readDesign Therapeutics (NASDAQ:DSGN) shares fell 4.5% during mid-day trading with increased volume, closing at $9.35. The company has a "Moderate Buy" consensus rating from analysts with an average target price of $14.00, despite some recent "sell" downgrades. Fundamentals show a market cap of $536.85 million and a negative PE ratio, though Q3 earnings beat estimates.
3 min readCARLSBAD, Calif., Nov. 26, 2025 ( GLOBE NEWSWIRE ) -- Design Therapeutics, Inc. ( NASDAQ:DSGN ) , a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that management will participate in fireside chats at the following upcoming ...
2 min readCARLSBAD, Calif., Nov. 26, 2025 ( GLOBE NEWSWIRE ) -- Design Therapeutics, Inc. ( Nasdaq: DSGN ) , a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that management will participate in fireside chats at the following upcoming ...
2 min read
